Clinical Trials
72 trialsEvaluation for NCI Surgery Branch Clinical Research Protocols
National Institutes of Health Clinical Center (CC)
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
National Cancer Institute (NCI)
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Institutes of Health Clinical Center (CC)
SunRISe-1
Janssen Research & Development, LLC
SunRISe-2
Janssen Research & Development, LLC
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Institutes of Health Clinical Center (CC)
TAR-210
Janssen Pharmaceutical K.K.
SunRISe-3
Janssen Research & Development, LLC
ARC-25
Arcus Biosciences, Inc.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
VOLGA
AstraZeneca
panSOHO
Bayer
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
FORAGER-2
Eli Lilly and Company
Quality of Life in Patients With Bladder Cancer
Memorial Sloan Kettering Cancer Center
TTBF
University of California, San Francisco
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
VIABLE
Virtuoso Surgical, Inc.
GAIN-BCG
Alliance for Clinical Trials in Oncology
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
First Affiliated Hospital of Fujian Medical University
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
DP-04
AstraZeneca
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
National Institutes of Health Clinical Center (CC)
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
National Institutes of Health Clinical Center (CC)
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
IMGeS
National Cancer Center, Korea
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
ENAiBLE
Photocure
TroFuse-031
Merck Sharp & Dohme LLC
Noninvasive Urine Testing for Urothelial Carcinoma
Henan Provincial People's Hospital
NILE
AstraZeneca
KEYNOTE-866
Merck Sharp & Dohme LLC
INTerpath-011
Merck Sharp & Dohme LLC
RIVERS
AstraZeneca
COARC
University of Texas Southwestern Medical Center
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
HOPE-07-MIBC
West China Hospital
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital
LORUP
Umeå University
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology